| Recruiting | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Short Bowel Syndrome | Phase 3 | 2026-02-11 |
| Completed | Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations Obesity & Overweight | Phase 1 | 2025-12-17 |
| Enrolling By Invitation | Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome Short Bowel Syndrome (SBS) | Phase 3 | 2025-12-11 |
| Active Not Recruiting | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) Overweight, Type 2 Diabetes, Obesity | Phase 2 | 2025-04-22 |
| Completed | Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function Renal Impairment | Phase 1 | 2025-04-15 |
| Completed | A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Overweight and Obesity | Phase 1 | 2024-12-23 |
| Completed | Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities Obesity | Phase 2 | 2024-12-09 |
| Recruiting | A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Volunteers | Phase 1 | 2024-11-12 |
| Terminated | A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Safety and Tolerability | Phase 1 | 2023-09-15 |
| Completed | A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With Hypoglycemia, Type 1 Diabetes | Phase 3 | 2023-05-09 |
| Withdrawn | Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass ( Hypoglycemia, Glucose Metabolism Disorders | Phase 2 | 2023-02-01 |
| Completed | A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Par Overweight, Healthy Volunteers, Obese | Phase 1 | 2022-11-07 |
| Completed | A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participa Overweight, Healthy Volunteers | Phase 1 | 2021-10-19 |
| Completed | The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Short Bowel Syndrome | Phase 3 | 2021-08-10 |
| Active Not Recruiting | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial Short Bowel Syndrome | Phase 3 | 2021-06-16 |
| Completed | A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP757 Healthy | EARLY_Phase 1 | 2020-10-26 |
| Completed | Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism Congenital Hyperinsulinism | Phase 2 / Phase 3 | 2020-06-19 |
| Completed | A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjec Healthy | Phase 1 | 2020-03-04 |
| Completed | Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Fun Renal Impairment | Phase 1 | 2019-12-10 |
| Completed | A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Healthy | EARLY_Phase 1 | 2019-06-14 |
| Active Not Recruiting | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS Short Bowel Syndrome | Phase 3 | 2019-05-07 |
| Active Not Recruiting | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyper Congenital Hyperinsulinism | Phase 3 | 2019-05-02 |
| Completed | A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients Wit Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | 2019-03-26 |
| Completed | A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyper Congenital Hyperinsulinism | Phase 3 | 2019-02-07 |
| Completed | Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compare Hypoglycemia | Phase 1 | 2018-11-07 |
| Completed | Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | 2018-11-01 |
| Completed | Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) Short Bowel Syndrome | Phase 3 | 2018-10-04 |
| Completed | Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children Hypoglycemia | Phase 3 | 2018-09-28 |
| Completed | A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | 2017-12-07 |
| Completed | Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections i Healthy Subjects | Phase 1 | 2017-09-04 |
| Completed | A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | 2017-06-28 |
| Completed | ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon Diabetes Mellitus Type 1 | Phase 2 | 2016-12-01 |
| Completed | Feasibility Trial Testing the Bionic Pancreas With ZP4207 Diabetes Mellitus, Type 1 | Phase 2 | 2016-11-01 |
| Completed | A Phase 2 Trial Testing ZP1848 in Patients With SBS Short Bowel Syndrome | Phase 2 | 2016-02-01 |
| Completed | Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Markete Hypoglycemia | Phase 2 | 2016-01-01 |
| Completed | Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4 Hypoglycemia | Phase 1 | 2015-04-01 |
| Completed | Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of Hypoglycemia | Phase 1 | 2014-12-01 |
| Completed | Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevat Focus of Study is STEMI | Phase 2 | 2013-11-01 |
| Completed | Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose Inflammatory Bowel Disease | Phase 1 | 2009-01-01 |
| Terminated | ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure Heart Failure, Congestive | Phase 2 | 2006-01-01 |